ARWR vs CRVS

Arrowhead Pharmaceuticals continues to demonstrate strong 10x growth potential within 3-5 years. The Q1 2026 financials (fiscal quarter ended Dec 31, 2025) showcased a significant revenue beat of $264.0M, driven by the successful commercial launch of Redemplo, and a positive net margin of 18.54%. Critically, the recently announced two-year efficacy data for plozasiran, showing an 83% triglyceride ...

Corvus Pharmaceuticals demonstrates significantly enhanced 10x potential, largely driven by compelling Phase 2 data for CPI-818 in T-cell lymphoma, a critical de-risking event. This clinical validation strengthens its market opportunity in high-unmet-need oncology niches and expands its competitive moat through proprietary IP and clinical efficacy. The leadership team, particularly Dr. Richard Mil...